Loading
Multi-cancer early detection blood tests take a decade to prove they save lives. Regulators could accept a fall in late-stage cancers as the first answer, validated against pooled data from completed screening trials, provided approval is conditional on continued mortality follow-up.
NHS-Galleri chose stage III/IV incidence as its primary endpoint; regulators have not said whether that suffices for approval or coverage. Propose a formal surrogate-validation exercise pooling individual data from completed screening RCTs (NLST, NELSON, UKCTOCS, ERSPC, Minnesota, NordICC) to estimate the trial-level correlation between late-stage incidence reduction and cancer-specific mortality reduction, and a conditional-approval pathway with mandated mortality follow-up.
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Stage shift.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Stage shift.
Shares NHS-Galleri, Stage shift, The hardest cancers are found late, Trial design, endpoints and cost.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Stage shift.
Shares NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test, Stage shift, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares PATHFINDER 2, NHS-Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/